Multiple White House officials are denying that President Donald Trump was the mystery patient who reportedly got early access to an experimental weight loss drug to treat severe health complications.
On Tuesday, health news site STAT reported that drug maker Eli Lilly and the Food and Drug Administration granted a 79-year-old access to retatrutide, a hotly anticipated treatment, under “compassionate use,” which allows patients with severe health issues to access experimental therapies.